2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(2-(2-(4-((4-((6-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-ylamino)pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethylamino)isoindoline-1,3-dione

ID: ALA4520866

PubChem CID: 155542441

Max Phase: Preclinical

Molecular Formula: C49H56F2N14O7

Molecular Weight: 991.07

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: Cc1nc2c(F)cc(-c3nc(Nc4ccc(CN5CCN(Cc6cn(CCOCCOCCOCCNc7cccc8c7C(=O)N(C7CCC(=O)NC7=O)C8=O)nn6)CC5)cn4)ncc3F)cc2n1C(C)C

Standard InChI: InChI=1S/C49H56F2N14O7/c1-30(2)64-31(3)55-45-36(50)23-33(24-40(45)64)44-37(51)26-54-49(58-44)56-41-9-7-32(25-53-41)27-61-12-14-62(15-13-61)28-34-29-63(60-59-34)16-18-71-20-22-72-21-19-70-17-11-52-38-6-4-5-35-43(38)48(69)65(47(35)68)39-8-10-42(66)57-46(39)67/h4-7,9,23-26,29-30,39,52H,8,10-22,27-28H2,1-3H3,(H,57,66,67)(H,53,54,56,58)

Standard InChI Key: ODKBPNWNYDPLSX-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 72 80  0  0  0  0  0  0  0  0999 V2000
    2.0599   -8.0398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7748   -8.4527    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4911   -8.0394    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4883   -7.2088    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7764   -9.2755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0602   -9.6872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0597  -10.5115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7746  -10.9250    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.4916  -10.5082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4885   -9.6854    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.0611   -7.2125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7688   -6.7972    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5926   -5.9959    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7759   -5.9157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4475   -6.6676    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2073  -10.9184    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.9205  -10.5035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6330  -10.9145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3456  -10.5004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3433   -9.6745    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6225   -9.2645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9128   -9.6810    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0559   -9.2587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7723   -9.6679    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7726  -10.4925    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4848  -10.9017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1998  -10.4894    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.1980   -9.6634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4812   -9.2498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3462   -9.2738    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    4.2013   -6.7937    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    1.3585   -5.2042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6418   -6.8448    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0855   -6.2355    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3923   -7.6311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9147  -10.9013    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6287  -10.4882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3792  -10.8207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.9307  -10.2072    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.5176   -9.4931    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.7108   -9.6653    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7541  -10.2042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1640   -9.4882    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9890   -9.4852    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.3989   -8.7692    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2239   -8.7662    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6338   -8.0502    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.4588   -8.0472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8687   -7.3312    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.6937   -7.3282    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.1036   -6.6122    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.9286   -6.6092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3385   -5.8932    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.1634   -5.8902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5746   -6.6036    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3988   -6.6009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.8096   -5.8844    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5671   -5.1753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.3873   -5.1710    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6367   -4.3897    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9706   -3.9110    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.3097   -4.3965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9699   -3.0887    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6841   -2.6738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.6817   -1.8560    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.9670   -1.4436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.2528   -1.8619    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.2534   -2.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5407   -3.0979    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   20.9641   -0.6186    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.5237   -4.1456    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.4200   -4.1307    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
 11  1  2  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4 12  2  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
  2  5  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 11  1  0
  9 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 17  1  0
 20 23  1  0
 23 24  1  0
 24 25  1  0
 24 29  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
  6 30  1  0
  4 31  1  0
 14 32  1  0
 15 33  1  0
 33 34  1  0
 33 35  1  0
 27 36  1  0
 36 37  1  0
 37 38  2  0
 38 39  1  0
 39 40  1  0
 40 41  2  0
 41 37  1  0
 39 42  1  0
 42 43  1  0
 43 44  1  0
 44 45  1  0
 45 46  1  0
 46 47  1  0
 47 48  1  0
 48 49  1  0
 49 50  1  0
 50 51  1  0
 51 52  1  0
 52 53  1  0
 53 54  1  0
 54 55  2  0
 55 56  1  0
 56 57  2  0
 57 59  1  0
 58 54  1  0
 58 59  2  0
 59 60  1  0
 60 61  1  0
 61 62  1  0
 62 58  1  0
 63 64  1  0
 63 68  1  0
 64 65  1  0
 65 66  1  0
 66 67  1  0
 67 68  1  0
 61 63  1  0
 68 69  2  0
 66 70  2  0
 62 71  2  0
 60 72  2  0
M  END

Associated Targets(Human)

CDK6 Tclin Protein cereblon/Cyclin-dependent kinase 6 (113 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK4 Tclin Protein cereblon/Cyclin-dependent kinase 4 (68 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 991.07	Molecular Weight (Monoisotopic): 990.4424	AlogP: 4.27	#Rotatable Bonds: 22
Polar Surface Area: 228.98	Molecular Species: NEUTRAL	HBA: 19	HBD: 3
#RO5 Violations: 2	HBA (Lipinski): 21	HBD (Lipinski): 3	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 10.25	CX Basic pKa: 6.43	CX LogP: 3.74	CX LogD: 3.69
Aromatic Rings: 6	Heavy Atoms: 72	QED Weighted: 0.06	Np Likeness Score: -1.30

References

1. Su S, Yang Z, Gao H, Yang H, Zhu S, An Z, Wang J, Li Q, Chandarlapaty S, Deng H, Wu W, Rao Y.. (2019) Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders., 62 (16): [PMID:31330105] [10.1021/acs.jmedchem.9b00871]
2. Fry, David W DW and 10 more authors. 2004-11 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. [PMID:15542782]
3. Squires, Matthew S MS and 7 more authors. 2009-02 Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [PMID:19174555]
4. Cirstea, D D and 15 more authors. 2013-12 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. [PMID:23807770]
5. Gelbert, Lawrence M LM and 16 more authors. 2014-10 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. [PMID:24919854]
6. Paiva, Cody C and 8 more authors. 2015 Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. [PMID:26606677]
7. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC. 2016-05 Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. [PMID:26826116]
8. Wang, Yan Y and 10 more authors. 2018-03-01 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. [PMID:29429832]
9. Zhi, Yanle Y and 9 more authors. 2018-07-15 Discovery of the selective and efficacious inhibitors of FLT3 mutations. [PMID:29894944]

2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(2-(2-(4-((4-((6-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-ylamino)pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethylamino)isoindoline-1,3-dione

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source